: To analyze the long-term local control, overall survival and toxicity in Carcinoma Buccal Mucosa patients treated with interstitial brachytherapy.
METHODS AND MATERIALS
: This analysis included patients diagnosed as Carcinoma Buccal Mucosa on biopsy and treated with radical brachytherapy or External Beam Radiotherapy (EBRT) followed by brachytherapy boost. All patients received High dose rate (HDR) interstitial brachytherapy. The total dose was 35 Gy in ten fractions for brachytherapy alone. Patients who received EBRT (50–54 Gy) were boosted by brachytherapy to a dose of 18–24 Gy in 6–8 fractions. All patients were treated using CT based planning.
: Between 2007 to 2017, a total of 24 patients of Carcinoma Buccal Mucosa received HDR interstitial brachytherapy either alone or as a boost. Majority of the patients were tobacco chewers (80%). 17(71%) patients were clinical stage T2N0M0 and 7(29%) were clinically T1N0M0. At a median follow up of 7 years (3–12 years), the local control rate was 100% in stage I and 88% in stage II. The 5 year overall survival rate was 80%. Two patients developed nodal recurrence and one patient developed distant metastasis within two years of treatment. Tumor size and brachytherapy technique (radical vs. boost) did not impact local control or overall survival (p > 0.05). Majority of the acute toxicities were Grade 1 and 2. One patient developed osteoradionecrosis of the mandible.
: Interstitial brachytherapy in early-stage Buccal Mucosa cancer either alone or as a boost provides excellent long term local control and overall survival. The acute and late toxicities are acceptable with majority of the patients presenting with Grade 1 or 2 toxicity.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Brachytherapy
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Periodontal diseases and risk of oral cancer in Southern India: results from the HeNCe Life study.Int. J. Canc. 2016; 139: 1512-1519https://doi.org/10.1002/ijc.30201
- Oral cancer statistics in India on the basis of first report of 29 population-based cancer registries.J. Oral Maxillofac. Pathol. 2018; 22: 18-26https://doi.org/10.4103/jomfp.JOMFP_113_17
- Evaluation of quality of life and the nutritional status of oral cancer treated patients as compared with the control group in Varanasi district: a cross sectional study.Int. J. Community Med. Public Heal. 2019; 6: 4804https://doi.org/10.18203/2394-6040.ijcmph20195059
Sunny L, Yeole BB, Hakama M, Shiri R, Sastry PSRK, Mathews S, Advani SH (2004). Oral cancers in Mumbai, India: a fifteen years perspective with respect to incidence trend and cumulative risk. Asian Pac J Cancer Prev; 5: 294-300
- GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas.Radiother Oncol. 2009; 91: 150-156
- Pulsed dose rate brachytherapy in head and neck cancers. Feasibility study of a French cooperative group.Radiother Oncol. 2001; 58: 71-75
- Safety aspects of pulsed dose rate brachytherapy: analysis of 1225 patients.Nowotwory. J Oncol. 2007; 57: e230-e232
- Quality of interstitial PDR-brachytherapy-implants of head-an-neck cancers: predictive factors for local control and late toxicity?.Radiother Oncol. 2007; 82: 167-173
- Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy.J Contemp Brachytherapy. 2015; 6: 404-416
- Efficacy of high dose-rate interstitial brachytherapy in patients with oral tongue carcinoma.Brachytherapy. 2010; 9: 227-234
- Hyperfractionated high-dose rate brachytherapy in the treatment of oral tongue cancer.Reports of practical oncology and radiotherapy. 2011; 16: 243-247
- Prognostic factors in squamous cell lip carcinoma treated with high-dose-rate brachytherapy.Head Neck. 2014; 36: 1737-1742
- Survival following primary surgery for oral cancer.Oral Oncol. 2009; 45 (Epub 2008 Jul 31. PMID: 18674959): 201-211https://doi.org/10.1016/j.oraloncology.2008.05.008
- Squamous cell carcinoma of buccal mucosa: an analysis of prognostic factors.South Asian J Cancer. 2018; 7: 49-54https://doi.org/10.4103/sajc.sajc_317_16
- GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross-sectional imaging-based treatment planning and stepping source technology.Radiother Oncol. 2017; 122: 248-254
- Brachytherapy in head and neck malignancies: indian Brachytherapy Society (IBS) recommendations and guidelines.J Contemp Brachytherapy. 2020; 12 (Epub 2020 Oct 30. PMID: 33299441; PMCID: PMC7701929): 501-511https://doi.org/10.5114/jcb.2020.100385
- American Brachytherapy Society. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma.Int J Radiat Oncol Biol Phys. 2001; 50 (PMID: 11483328): 1190-1198https://doi.org/10.1016/s0360-3016(01)01567-x
- Acquisition of equal or better planning results with interstitial brachytherapy when compared with intensity modulated radiotherapy in tongue cancers.Brachytherapy. 2010; 9: 235-238
- Role of high dose rate interstitial brachytherapy in early and locally advanced squamous cell carcinoma of buccal mucosa.Springerplus. 2014; 3 (PMID: 25332889; PMCID: PMC4197196): 590https://doi.org/10.1186/2193-1801-3-590
- High-dose-rate interstitial brachytherapy in oral cancer – its impact on quality of life.Brachytherapy. 2016; 15: 381-386
- Brachytherapy for buccal cancer: from conventional low dose rate (LDR) or mold technique to high dose rate interstitial brachytherapy (HDR-ISBT).Anticancer Res. 2017; 37: 6887-6892
Published online: December 04, 2021
Accepted: October 14, 2021
Received in revised form: September 26, 2021
Received: April 24, 2021
© 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.